Showing 5971-5980 of 7022 results for "".
- Jury Still Out on Environmental Effects of Chemical Sunscreenshttps://practicaldermatology.com/news/jury-still-out-on-environmental-effects-of-chemical-sunscreens/2457705/In the wake of Hawaiian legislation banning the sale and distribution of sunscreens containing oxybenzone and octinoxate because they may contribute to coral bleaching, new research reviews the available data on chemical ultraviolet filters found in U.S. sunscreens. The
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod
- FDA Approves Dermira's Qbrexza Cloth to Treat Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-delmiras-qbrexza-cloth-to-treat-primary-axillary-hyperhidrosis/2457709/The FDA has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is applied directly to the skin and is designed to block sweat production by inhib
- LEO Pharma and Advancing Innovation in Dermatology Partner to Help Finance Accelerator Fundhttps://practicaldermatology.com/news/leo-pharma-and-advancing-innovation-in-dermatology-partner-to-help-finance-accelerator-fund/2457713/LEO Pharma and its Boston-based R&D innovation unit LEO Science & Tech Hub, and Advancing Innovation in Dermatology (AID) will each contribute $500,000 into the recently created Advancing Innovation in Dermatology Accelerator Fund. This non-profit fund is unique in its approach for suppor
- UVBioTek Launches POLY Go Portable LED Light Therapyhttps://practicaldermatology.com/news/uvbiotek-launches-poly-go-portable-led-light-therapy/2457714/UVBioTek has launched a new line of hand-held LED therapy products that support their newest brand, POLY LED Light Therapy. The mobile hand-held products, named “POLY Go”, use multiple wavelengths that are clinically proven to cater to those with acne, fine-
- First EB Patient Enrolled in PK Study of Diacerein 1% Ointmenthttps://practicaldermatology.com/news/first-eb-patient-enrolled-in-pk-study-of-diacerein-1-ointment/2457716/The first patient has been enrolled in a new Phase 1 study evaluating the pharmacokinetics (PK) and safety of Castle Creek Pharmaceuticals’ diacerein 1% ointment (CCP-020) under maximum use conditions in patients with epidermolysis bullosa (EB)
- CBD Naturals to Introduce New Skincare Linehttps://practicaldermatology.com/news/cbd-naturals-to-introduce-new-skincare-line/2457717/Delivering natural beauty from the inside out, CBD Naturals® will introduce Floré™, a prestigious new line of skincare products, at the International Cannabis Business Conference in Vancouver on June 25. Floré™ incorporates cutting-edge ingredient formulas that
- Restoration Robotics Launches Continuing Education Master Class for ARTAS Systemhttps://practicaldermatology.com/news/restoration-robotics-launches-continuing-education-master-class-for-artas-system/2457729/Restoration Robotics, Inc. is launching a continuing education Master Class Series for its ARTAS® Robotic Hair Restoration System to train physicians on best practices and the most up-to-date techniques for the technology. The Master Class Series will enable users to provide exceptional
- ThermiVa: First-ever Data Show Vaginal Regenerationhttps://practicaldermatology.com/news/thermiva-first-ever-data-show-vaginal-regeneration/2457730/Thermi’s ThermiVa® device has been shown to deliver significant improvements in common vaginal disorders and improve sexual satisfaction, according to a study published in Dermatologic Surgery. Since it was cleared by the FDA in 2013, ThermiVa has been used
- Opdivo Data: Superior Recurrence-Free Survival Versus Ipilimumabhttps://practicaldermatology.com/news/opdivo-data-superior-recurrence-free-survival-versus-ipilimumab/2457734/Updated results from the Phase 3 CheckMate -238 trial evaluating Opdivo (nivolumab, Bristol-Myers Squibb Company) versus Yervoy (ipilimumab, Bristol-Myers Squibb Company) in patients with stage IIIB/C or stage IV melanoma who are at high ri